Importantly, the patient samples used for these experiments no longer focus on infant ALL with MLL rearrangements, but reflect a wider range of different ALL subtypes, including high-risk Philadelphia chromosome-positive and BCR-ABL1-like ALL, intermediate risk ALL with no known cytogenetic risk factors and prognostically more favourable ALL with high hyperdiploidy (Table 1). The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.